annotation_id large_string | subject large_string | rsid large_string | gene large_string | genotype large_string | evidence_level large_string | phenotype_category large_string | drugs large_string | phenotypes large_string | annotation_text large_string | url large_string |
|---|---|---|---|---|---|---|---|---|---|---|
982037423 | CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10 | null | CYP2D6 | *1 | 1A | Metabolism/PK | venlafaxine | Depressive Disorder;Obsessive-Compulsive Disorder | The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of venlafaxine as compared to patients carrying two increased function alleles or an increased function allele in c... | https://www.clinpgx.org/clinicalAnnotation/982037423 |
982037423 | CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10 | null | CYP2D6 | *10 | 1A | Metabolism/PK | venlafaxine | Depressive Disorder;Obsessive-Compulsive Disorder | The CYP2D6*10 allele has been assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the *10 allele in combination with a decreased or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer pheno... | https://www.clinpgx.org/clinicalAnnotation/982037423 |
982037423 | CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10 | null | CYP2D6 | *3 | 1A | Metabolism/PK | venlafaxine | Depressive Disorder;Obsessive-Compulsive Disorder | The CYP2D6*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *3 a... | https://www.clinpgx.org/clinicalAnnotation/982037423 |
982037423 | CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10 | null | CYP2D6 | *4 | 1A | Metabolism/PK | venlafaxine | Depressive Disorder;Obsessive-Compulsive Disorder | The CYP2D6*4 allele has been assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 a... | https://www.clinpgx.org/clinicalAnnotation/982037423 |
982037423 | CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10 | null | CYP2D6 | *5 | 1A | Metabolism/PK | venlafaxine | Depressive Disorder;Obsessive-Compulsive Disorder | The CYP2D6*5 allele has been assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 a... | https://www.clinpgx.org/clinicalAnnotation/982037423 |
982037423 | CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10 | null | CYP2D6 | *6 | 1A | Metabolism/PK | venlafaxine | Depressive Disorder;Obsessive-Compulsive Disorder | The CYP2D6*6 allele has been assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have decreased metabolism of venlafaxine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 a... | https://www.clinpgx.org/clinicalAnnotation/982037423 |
982037557 | rs11706052 | rs11706052 | IMPDH2 | AA | 4 | Efficacy;Toxicity | mycophenolate mofetil;mycophenolic acid | Kidney Transplantation | Patients with the AA genotype may have 1) a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the GA or GG genotype and 2) an increased incidence of lymphopenia as compared to patients with the GA genotype. However, the AA genotype influence is controversy dis... | https://www.clinpgx.org/clinicalAnnotation/982037557 |
982037557 | rs11706052 | rs11706052 | IMPDH2 | GA | 4 | Efficacy;Toxicity | mycophenolate mofetil;mycophenolic acid | Kidney Transplantation | Patients with the GA genotype may have 1) an increased risk for acute rejection after kidney transplantation and 2) decreased incidence of lymphopenia as compared to patients with the AA genotype but the GA genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also ... | https://www.clinpgx.org/clinicalAnnotation/982037557 |
982037557 | rs11706052 | rs11706052 | IMPDH2 | GG | 4 | Efficacy;Toxicity | mycophenolate mofetil;mycophenolic acid | Kidney Transplantation | Patients with the GG genotype may have an increased risk for acute rejection after kidney transplantation as compared to patients with the AA genotype but the GG genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejectio... | https://www.clinpgx.org/clinicalAnnotation/982037557 |
982037571 | rs2242480 | rs2242480 | CYP3A4 | CC | 4 | Efficacy | clopidogrel | Coronary Artery Disease | Patients with the CC (CYP3A4 *1/*1) genotype may be less likely to respond to clopidogrel as compared to patients with the CT or TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel. | https://www.clinpgx.org/clinicalAnnotation/982037571 |
982037571 | rs2242480 | rs2242480 | CYP3A4 | CT | 4 | Efficacy | clopidogrel | Coronary Artery Disease | Patients with the CT (CYP3A4 *1/*1G) genotype may be more likely to respond to clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel. | https://www.clinpgx.org/clinicalAnnotation/982037571 |
982037571 | rs2242480 | rs2242480 | CYP3A4 | TT | 4 | Efficacy | clopidogrel | Coronary Artery Disease | Patients with the TT (CYP3A4 *1G/*1G genotype may be more likely to respond to clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel. | https://www.clinpgx.org/clinicalAnnotation/982037571 |
982037603 | CYP2C9*1, CYP2C9*2, CYP2C9*3 | null | CYP2C9 | *1 | 4 | Efficacy | clopidogrel | Acute coronary syndrome;Coronary Artery Disease | Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have 1) increased inhibition of platelet aggregation and 2) decreased, but not absent, risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with two decreased or no function alleles ... | https://www.clinpgx.org/clinicalAnnotation/982037603 |
982037603 | CYP2C9*1, CYP2C9*2, CYP2C9*3 | null | CYP2C9 | *2 | 4 | Efficacy | clopidogrel | Acute coronary syndrome;Coronary Artery Disease | Patients carrying the CYP2C9*2 allele in combination with a normal, decreased or no function allele may have 1) decreased inhibition of platelet aggregation and 2) increased risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with two normal function alleles. However, contr... | https://www.clinpgx.org/clinicalAnnotation/982037603 |
982037603 | CYP2C9*1, CYP2C9*2, CYP2C9*3 | null | CYP2C9 | *3 | 4 | Efficacy | clopidogrel | Acute coronary syndrome;Coronary Artery Disease | Patients carrying the CYP2C9*3 allele in combination with a normal, decreased or no function allele may have 1) decreased inhibition of platelet aggregation and 2) increased risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with two normal function alleles. However, contr... | https://www.clinpgx.org/clinicalAnnotation/982037603 |
982037753 | rs1137101 | rs1137101 | LEPR | AA | 3 | Efficacy | simvastatin | Hyperlipidemias | Patients with the AA genotype and hypercholesterolemia may have a better response to treatment with increased reductions in total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment. | https://www.clinpgx.org/clinicalAnnotation/982037753 |
982037753 | rs1137101 | rs1137101 | LEPR | AG | 3 | Efficacy | simvastatin | Hyperlipidemias | Patients with the AG genotype and hypercholesterolemia may have a better response to treatment with increased reductions in total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment. | https://www.clinpgx.org/clinicalAnnotation/982037753 |
982037753 | rs1137101 | rs1137101 | LEPR | GG | 3 | Efficacy | simvastatin | Hyperlipidemias | Patients with the GG genotype and hypercholesterolemia may have a reduced response to treatment with less reduction in total cholesterol when treated with simvastatin compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment. | https://www.clinpgx.org/clinicalAnnotation/982037753 |
982037796 | rs1137101 | rs1137101 | LEPR | AA | 3 | Efficacy | simvastatin | Coronary Disease | Patients with the AA genotype and coronary heart disease may have a reduced response to treatment with smaller increases in HDL-C levels when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment. | https://www.clinpgx.org/clinicalAnnotation/982037796 |
982037796 | rs1137101 | rs1137101 | LEPR | AG | 3 | Efficacy | simvastatin | Coronary Disease | Patients with the AG genotype and coronary heart disease may have a reduced response to treatment with smaller increases in HDL-C levels when treated with simvastatin as compared to patients with the GG genotype or may have a better response to treatment with higher increases in HDL-C levels when treated with simvastat... | https://www.clinpgx.org/clinicalAnnotation/982037796 |
982037796 | rs1137101 | rs1137101 | LEPR | GG | 3 | Efficacy | simvastatin | Coronary Disease | Patients with the GG genotype and coronary heart disease may have a better response to treatment with higher increases in HDL-C levels when treated with simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment. | https://www.clinpgx.org/clinicalAnnotation/982037796 |
982037811 | rs708272 | rs708272 | CETP | AA | 3 | Efficacy | pravastatin | Coronary Artery Disease | Patients with the AA genotype and Coronary Artery Disease may be less likely to benefit from treatment with pravastatin and have an increased risk of death or cardiovascular disease events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to statin ... | https://www.clinpgx.org/clinicalAnnotation/982037811 |
982037811 | rs708272 | rs708272 | CETP | AG | 3 | Efficacy | pravastatin | Coronary Artery Disease | Patients with the AG genotype and Coronary Artery Disease may be more likely to benefit from treatment with pravastatin and have a reduced risk of cardiovascular disease events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. | https://www.clinpgx.org/clinicalAnnotation/982037811 |
982037811 | rs708272 | rs708272 | CETP | GG | 3 | Efficacy | pravastatin | Coronary Artery Disease | Patients with the GG genotype and Coronary Artery Disease may be more likely to benefit from treatment with pravastatin and have a reduced risk of death or cardiovascular disease events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin tre... | https://www.clinpgx.org/clinicalAnnotation/982037811 |
982038273 | rs7997012 | rs7997012 | HTR2A | AA | 3 | Efficacy | venlafaxine | Anxiety Disorders | Patients with the AA genotype may be less likely to respond to venlafaxine as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine. | https://www.clinpgx.org/clinicalAnnotation/982038273 |
982038273 | rs7997012 | rs7997012 | HTR2A | GA | 3 | Efficacy | venlafaxine | Anxiety Disorders | Patients with the GA genotype may be more likely to respond to venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine. | https://www.clinpgx.org/clinicalAnnotation/982038273 |
982038273 | rs7997012 | rs7997012 | HTR2A | GG | 3 | Efficacy | venlafaxine | Anxiety Disorders | Patients with the GG genotype may be more likely to respond to venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine. | https://www.clinpgx.org/clinicalAnnotation/982038273 |
982040423 | rs6785930 | rs6785930 | P2RY12 | AA | 4 | Efficacy;Toxicity | clopidogrel | null | Patients with the AA genotype who are treated with clopidogrel may have an increased risk of neurological events as compared to patients with the GG genotype. However, no association with differences in risk of cardiovascular events was reported. Other genetic and clinical factors may also influence a patient's respons... | https://www.clinpgx.org/clinicalAnnotation/982040423 |
982040423 | rs6785930 | rs6785930 | P2RY12 | AG | 4 | Efficacy;Toxicity | clopidogrel | null | Patients with the AG genotype who are treated with clopidogrel may have an increased risk of neurological events as compared to patients with the GG genotype. However, no association with differences in risk of cardiovascular events was reported. Other genetic and clinical factors may also influence a patient's respons... | https://www.clinpgx.org/clinicalAnnotation/982040423 |
982040423 | rs6785930 | rs6785930 | P2RY12 | GG | 4 | Efficacy;Toxicity | clopidogrel | null | Patients with the GG genotype who are treated with clopidogrel may have a decreased, but not absent, risk of neurological events as compared to patients with the AA genotype. However, no association with differences in risk of cardiovascular events was reported. Other genetic and clinical factors may also influence a p... | https://www.clinpgx.org/clinicalAnnotation/982040423 |
982040494 | rs6265 | rs6265 | BDNF | CC | 3 | Efficacy | paroxetine | Major Depressive Disorder | Patients with the CC genotype and Depressive Disorder may be more likely to respond to paroxetine as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to paroxetine. | https://www.clinpgx.org/clinicalAnnotation/982040494 |
982040494 | rs6265 | rs6265 | BDNF | CT | 3 | Efficacy | paroxetine | Major Depressive Disorder | Patients with the CT genotype and Depressive Disorder may be more likely to respond to paroxetine as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to paroxetine. | https://www.clinpgx.org/clinicalAnnotation/982040494 |
982040494 | rs6265 | rs6265 | BDNF | TT | 3 | Efficacy | paroxetine | Major Depressive Disorder | Patients with the TT genotype and Depressive Disorder may be less likely to respond to paroxetine as compared to patients with the CT or CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to paroxetine. | https://www.clinpgx.org/clinicalAnnotation/982040494 |
982040598 | rs4244285 | rs4244285 | CYP2C19 | AA | 3 | Efficacy | prasugrel | Acute coronary syndrome | Patients with the AA genotype who are treated with prasugrel may have a higher rate of high on-treatment platelet reactivity at 1 month of treatment as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to p... | https://www.clinpgx.org/clinicalAnnotation/982040598 |
982040598 | rs4244285 | rs4244285 | CYP2C19 | AG | 3 | Efficacy | prasugrel | Acute coronary syndrome | Patients with the AG genotype who are treated with prasugrel may have a higher rate of high on-treatment platelet reactivity at 1 month of treatment as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to p... | https://www.clinpgx.org/clinicalAnnotation/982040598 |
982040598 | rs4244285 | rs4244285 | CYP2C19 | GG | 3 | Efficacy | prasugrel | Acute coronary syndrome | Patients with the GG genotype who are treated with prasugrel may have a lower rate of high on-treatment platelet reactivity at 1 month of treatment as compared to patients with the AG or AA genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response... | https://www.clinpgx.org/clinicalAnnotation/982040598 |
982040619 | rs2032582 | rs2032582 | ABCB1 | AA | 3 | Efficacy | cyclosporine;mycophenolate mofetil | Kidney Transplantation | Patients with the AA genotype may have an increased risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil... | https://www.clinpgx.org/clinicalAnnotation/982040619 |
982040619 | rs2032582 | rs2032582 | ABCB1 | AC | 3 | Efficacy | cyclosporine;mycophenolate mofetil | Kidney Transplantation | Patients with the AC genotype may have an increased risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil... | https://www.clinpgx.org/clinicalAnnotation/982040619 |
982040619 | rs2032582 | rs2032582 | ABCB1 | CC | 3 | Efficacy | cyclosporine;mycophenolate mofetil | Kidney Transplantation | Patients with the CC genotype may have a decreased, but not absent, risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to... | https://www.clinpgx.org/clinicalAnnotation/982040619 |
982040676 | rs17868320 | rs17868320 | UGT1A9 | CC | 4 | Efficacy | mycophenolate mofetil | Kidney Transplantation | Patients with the CC genotype who are treated with mycophenolate mofetil may have 1) no changes in mycophenolic acid exposure-related parameters and 2) a decreased, but not absent, risk of acute allograft rejection within 3 month after transplantation as compared to patients with the TT genotype. However, contradictory... | https://www.clinpgx.org/clinicalAnnotation/982040676 |
982040676 | rs17868320 | rs17868320 | UGT1A9 | TC | 4 | Efficacy | mycophenolate mofetil | Kidney Transplantation | Patients with the TC genotype who are treated with mycophenolate mofetil may have 1) changes in mycophenolic acid exposure-related parameters and 2) increased risk of acute allograft rejection within 3 month after transplantation as compared to patients with the CC genotype. However, contradictory findings are reported... | https://www.clinpgx.org/clinicalAnnotation/982040676 |
982040676 | rs17868320 | rs17868320 | UGT1A9 | TT | 4 | Efficacy | mycophenolate mofetil | Kidney Transplantation | Patients with the TT genotype who are treated with mycophenolate mofetil may have 1) changes in mycophenolic acid exposure-related parameters and 2) increased risk of acute allograft rejection within 3 month after transplantation as compared to patients with the CC genotype. However, contradictory findings are reported... | https://www.clinpgx.org/clinicalAnnotation/982040676 |
982040717 | rs1065776 | rs1065776 | P2RY1 | CC | 3 | Efficacy | aspirin | Myocardial Infarction | Patients with CC genotype were not studied but patients with the CT genotype who are treated with aspirin may have an increased risk of an aspirin-resistant phenotype as compared to patients with the TT genotype. However, contradictory findings are reported for C allele carriers. Other genetic and clinical factors may ... | https://www.clinpgx.org/clinicalAnnotation/982040717 |
982040717 | rs1065776 | rs1065776 | P2RY1 | CT | 3 | Efficacy | aspirin | Myocardial Infarction | Patients with the CT genotype who are treated with aspirin may have an increased risk of an aspirin-resistant phenotype as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin. | https://www.clinpgx.org/clinicalAnnotation/982040717 |
982040717 | rs1065776 | rs1065776 | P2RY1 | TT | 3 | Efficacy | aspirin | Myocardial Infarction | Patients with the TT genotype who are treated with aspirin may have a decreased, but not absent, risk of an aspirin-resistant phenotype as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin. | https://www.clinpgx.org/clinicalAnnotation/982040717 |
982042110 | rs2010851 | rs2010851 | WNT5B | AA | 3 | Other | fluorouracil | Colonic Neoplasms | Colon cancer patients with AA genotype may have longer time to tumor recurrence when treated 5-fluorouracil compared to patients with CC genotypes. Other genetic and clinical factors may also influence the tumor recurrence time. | https://www.clinpgx.org/clinicalAnnotation/982042110 |
982042110 | rs2010851 | rs2010851 | WNT5B | CA | 3 | Other | fluorouracil | Colonic Neoplasms | Colon cancer patients with CA genotype may have longer time to tumor recurrence when treated 5-fluorouracil compared to patients with CC genotypes. Other genetic and clinical factors may also influence the tumor recurrence time. | https://www.clinpgx.org/clinicalAnnotation/982042110 |
982042110 | rs2010851 | rs2010851 | WNT5B | CC | 3 | Other | fluorouracil | Colonic Neoplasms | Colon cancer patients with CC genotype may have shorter time to tumor recurrence when treated 5-fluorouracil compared to patients with CA + AA genotypes. Other genetic and clinical factors may also influence the tumor recurrence time. | https://www.clinpgx.org/clinicalAnnotation/982042110 |
982043234 | rs1937840 | rs1937840 | AKR1C3 | CC | 3 | Efficacy | docetaxel;doxorubicin | Breast Neoplasms | Patients with breast cancer and the rs1937840 CC genotype may have a decreased response to treatment with docetaxel and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with docetaxel and doxorubicin. | https://www.clinpgx.org/clinicalAnnotation/982043234 |
982043234 | rs1937840 | rs1937840 | AKR1C3 | CG | 3 | Efficacy | docetaxel;doxorubicin | Breast Neoplasms | Patients with breast cancer and the rs1937840 CG genotype may have a decreased response to treatment with docetaxel and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with docetaxel and doxorubicin. | https://www.clinpgx.org/clinicalAnnotation/982043234 |
982043234 | rs1937840 | rs1937840 | AKR1C3 | GG | 3 | Efficacy | docetaxel;doxorubicin | Breast Neoplasms | Patients with breast cancer and the rs1937840 GG genotype may have an increased response to treatment with docetaxel and doxorubicin as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence response to treatment with docetaxel and doxorubicin. | https://www.clinpgx.org/clinicalAnnotation/982043234 |
982044867 | rs9344 | rs9344 | CCND1 | AA | 3 | Efficacy | fluorouracil | Colonic Neoplasms | Patients with colonic neoplasms and the rs9344 AA genotype may have decreased time-to-tumor recurrence when treated with fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to fluorouracil. | https://www.clinpgx.org/clinicalAnnotation/982044867 |
982044867 | rs9344 | rs9344 | CCND1 | AG | 3 | Efficacy | fluorouracil | Colonic Neoplasms | Patients with colonic neoplasms and the rs9344 AG genotype may have increased time-to-tumor recurrence when treated with fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fluorouracil. | https://www.clinpgx.org/clinicalAnnotation/982044867 |
982044867 | rs9344 | rs9344 | CCND1 | GG | 3 | Efficacy | fluorouracil | Colonic Neoplasms | Patients with colonic neoplasms and the rs9344 GG genotype may have increased time-to-tumor recurrence when treated with fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fluorouracil. | https://www.clinpgx.org/clinicalAnnotation/982044867 |
982045076 | rs11252394 | rs11252394 | null | AA | 3 | Efficacy | salbutamol | Asthma | Patients with AA genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045076 |
982045076 | rs11252394 | rs11252394 | null | AG | 3 | Efficacy | salbutamol | Asthma | Patients with AG genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045076 |
982045076 | rs11252394 | rs11252394 | null | GG | 3 | Efficacy | salbutamol | Asthma | Patients with GG genotypes may have decreased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with AA genotypes. Other genetic and clinical factors may also influence a patient's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045076 |
982045082 | rs6988229 | rs6988229 | COL22A1 | CC | 3 | Efficacy | salbutamol | Asthma | Patients with CC genotypes may have decreased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045082 |
982045082 | rs6988229 | rs6988229 | COL22A1 | TC | 3 | Efficacy | salbutamol | Asthma | Patients with TC genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045082 |
982045082 | rs6988229 | rs6988229 | COL22A1 | TT | 3 | Efficacy | salbutamol | Asthma | Patients with TT genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045082 |
982045124 | rs9934438 | rs9934438 | VKORC1 | AA | 3 | Efficacy | fluindione | Thromboembolism | Patients with AA genotypes may have decreased the time to achieve a first INR within the therapeutic range and shorter time to have over-anticoagulation (INR >4) risk when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045124 |
982045124 | rs9934438 | rs9934438 | VKORC1 | AG | 3 | Efficacy | fluindione | Thromboembolism | Patients with AG genotypes may have decreased the time to achieve a first INR within the therapeutic range and shorter time to have over-anticoagulation (INR >4) risk when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045124 |
982045124 | rs9934438 | rs9934438 | VKORC1 | GG | 3 | Efficacy | fluindione | Thromboembolism | Patients with GG genotypes may have increased the time to achieve a first INR within the therapeutic range and longer time to have over-anticoagulation (INR >4) risk when compared to patients with AA genotypes. Other genetic and clinical factors may also influence a patient's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045124 |
982045137 | rs1801262 | rs1801262 | NEUROD1 | CC | 3 | Efficacy | repaglinide | Diabetes Mellitus | Patients with CC genotypes may have worse response for fasting and postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with CT + TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045137 |
982045137 | rs1801262 | rs1801262 | NEUROD1 | CT | 3 | Efficacy | repaglinide | Diabetes Mellitus | Patients with CT + TT genotypes may have better response for fasting and postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045137 |
982045137 | rs1801262 | rs1801262 | NEUROD1 | TT | 3 | Efficacy | repaglinide | Diabetes Mellitus | Patients with CT + TT genotypes may have better response for fasting and postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045137 |
982045146 | rs114202595 | rs114202595 | PAX4 | AA | 3 | Efficacy | repaglinide | Diabetes Mellitus | Patients with AA + AG genotypes may have better response for postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045146 |
982045146 | rs114202595 | rs114202595 | PAX4 | AG | 3 | Efficacy | repaglinide | Diabetes Mellitus | Patients with AA + AG genotypes may have better response for postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045146 |
982045146 | rs114202595 | rs114202595 | PAX4 | GG | 3 | Efficacy | repaglinide | Diabetes Mellitus | Patients with GG genotypes may have worse response for postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with AA +AG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045146 |
982045465 | rs9934438 | rs9934438 | VKORC1 | AA | 3 | Efficacy | warfarin | null | Subjects with AA genotypes may have increased ratio of (R)-warfarin / (S)-warfarin AUC prothrombin time when compared to subjects with GG genotypes. Other genetic and clinical factors may also influence a subject's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045465 |
982045465 | rs9934438 | rs9934438 | VKORC1 | AG | 3 | Efficacy | warfarin | null | Subjects with AG genotypes may have increased ratio of (R)-warfarin / (S)-warfarin AUC prothrombin time when compared to subjects with GG genotypes. Other genetic and clinical factors may also influence a subject's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045465 |
982045465 | rs9934438 | rs9934438 | VKORC1 | GG | 3 | Efficacy | warfarin | null | Subjects with GG genotypes may have decreased ratio of (R)-warfarin / (S)-warfarin AUC prothrombin time when compared to subjects with AA genotypes. Other genetic and clinical factors may also influence a subject's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045465 |
982045674 | rs2069502 | rs2069502 | CDK4 | CC | 3 | Other | somatropin recombinant | Turner Syndrome | Patient with CC genotype may have decreased IGF-I response when treated with somatropin recombinant in children with Turner Syndrome as compared to patients with CT + TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045674 |
982045674 | rs2069502 | rs2069502 | CDK4 | CT | 3 | Other | somatropin recombinant | Turner Syndrome | Patient with CT + TT genotypes may have increased IGF-I response when treated with somatropin recombinant in children with Turner Syndrome as compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045674 |
982045674 | rs2069502 | rs2069502 | CDK4 | TT | 3 | Other | somatropin recombinant | Turner Syndrome | Patient with CT + TT genotypes may have increased IGF-I response when treated with somatropin recombinant in children with Turner Syndrome as compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045674 |
982045698 | rs2270777 | rs2270777 | CDK4 | CC | 3 | Other | somatropin recombinant | null | Patient with CC + CT genotypes may have a decreased IGF-I response when treated with somatropin recombinant in children with growth hormone deficiency as compared to patients with TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045698 |
982045698 | rs2270777 | rs2270777 | CDK4 | CT | 3 | Other | somatropin recombinant | null | Patient with CT + CC genotypes may have a decreased IGF-I response when treated with somatropin recombinant in children with growth hormone deficiency as compared to patients with TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045698 |
982045698 | rs2270777 | rs2270777 | CDK4 | TT | 3 | Other | somatropin recombinant | null | Patient with TT genotypes may have an increased IGF-I response when treated with somatropin recombinant in children with growth hormone deficiency as compared to patients with CC + CT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy. | https://www.clinpgx.org/clinicalAnnotation/982045698 |
982046070 | CYP2C8*1, CYP2C8*2, CYP2C8*3 | null | CYP2C8 | *1/*1 | 3 | Other | pioglitazone | null | Patients with *1/*1 genotypes may have increased pioglitazone metabolism as compared to patients with the *2 or *3 alleles. Other genetic and clinical factors may also influence the metabolism and response to pioglitazone. | https://www.clinpgx.org/clinicalAnnotation/982046070 |
982046070 | CYP2C8*1, CYP2C8*2, CYP2C8*3 | null | CYP2C8 | *2 | 3 | Other | pioglitazone | null | Patients with the *2 allele may have decreased pioglitazone metabolism as compared to patients with *1/*1 genotypes. Other genetic and clinical factors may also influence the metabolism and response to pioglitazone. | https://www.clinpgx.org/clinicalAnnotation/982046070 |
982046070 | CYP2C8*1, CYP2C8*2, CYP2C8*3 | null | CYP2C8 | *3 | 3 | Other | pioglitazone | null | Patients with the *3 allele may have decreased plasma concentration and increased clearance when exposed to pioglitazone as compared to patients with *1/*1 genotypes. Other genetic and clinical factors may also influence the metabolism and response to pioglitazone. | https://www.clinpgx.org/clinicalAnnotation/982046070 |
982046386 | rs61767072 | rs61767072 | ADRA2C | GGGGCGGGGCCG/GGGGCGGGGCCG | 3 | Efficacy | bucindolol | Heart Failure | Patients with the GGGGCGGGGCCG/GGGGCGGGGCCG genotype and heart failure may have increased response to bucindolol as compared to patients with the GGGGCGGGGCCG/del or del/del genotype. Other genetic and clinical factors may also influence a patient's response to bucindolol. | https://www.clinpgx.org/clinicalAnnotation/982046386 |
982046386 | rs61767072 | rs61767072 | ADRA2C | GGGGCGGGGCCG/del | 3 | Efficacy | bucindolol | Heart Failure | Patients with the GGGGCGGGGCCG/del genotype and heart failure may have decreased response to bucindolol as compared to patients with the GGGGCGGGGCCG/GGGGCGGGGCCG genotype. Other genetic and clinical factors may also influence a patient's response to bucindolol. | https://www.clinpgx.org/clinicalAnnotation/982046386 |
982046386 | rs61767072 | rs61767072 | ADRA2C | del/del | 3 | Efficacy | bucindolol | Heart Failure | Patients with the GGGGCGGGGCCG/GGGGCGGGGCCG genotype and heart failure may have decreased response to bucindolol as compared to patients with the GGGGCGGGGCCG/GGGGCGGGGCCG genotype. Other genetic and clinical factors may also influence a patient's response to bucindolol. | https://www.clinpgx.org/clinicalAnnotation/982046386 |
982047500 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11, CYP2C9*13, CYP2C9*14, CYP2C9*16, CYP2C9*29, CYP2C9*31, CYP2C9*33, CYP2C9*37, CYP2C9*39, CYP2C9*42, CYP2C9*43, CYP2C9*45, CYP2C9*50, CYP2C9*52, CYP2C9*55 | null | CYP2C9 | *1 | 1A | Metabolism/PK | phenytoin | Epilepsy | The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, ... | https://www.clinpgx.org/clinicalAnnotation/982047500 |
982047500 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11, CYP2C9*13, CYP2C9*14, CYP2C9*16, CYP2C9*29, CYP2C9*31, CYP2C9*33, CYP2C9*37, CYP2C9*39, CYP2C9*42, CYP2C9*43, CYP2C9*45, CYP2C9*50, CYP2C9*52, CYP2C9*55 | null | CYP2C9 | *11 | 1A | Metabolism/PK | phenytoin | Epilepsy | The CYP2C9*11 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *11 allele in combination with a normal, decreased, or no function allele may have decreased metabolism/clearance of phenytoin as compared to patients with two normal function alleles. However, conflicting evidence has ... | https://www.clinpgx.org/clinicalAnnotation/982047500 |
982047500 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11, CYP2C9*13, CYP2C9*14, CYP2C9*16, CYP2C9*29, CYP2C9*31, CYP2C9*33, CYP2C9*37, CYP2C9*39, CYP2C9*42, CYP2C9*43, CYP2C9*45, CYP2C9*50, CYP2C9*52, CYP2C9*55 | null | CYP2C9 | *13 | 1A | Metabolism/PK | phenytoin | Epilepsy | The CYP2C9*13 allele has been assigned as a no function allele by CPIC. Patients carrying the *13 allele in combination with a normal, decreased, or no function allele may have decreased metabolism/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacok... | https://www.clinpgx.org/clinicalAnnotation/982047500 |
982047500 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11, CYP2C9*13, CYP2C9*14, CYP2C9*16, CYP2C9*29, CYP2C9*31, CYP2C9*33, CYP2C9*37, CYP2C9*39, CYP2C9*42, CYP2C9*43, CYP2C9*45, CYP2C9*50, CYP2C9*52, CYP2C9*55 | null | CYP2C9 | *14 | 1A | Metabolism/PK | phenytoin | Epilepsy | The CYP2C9*14 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *14 allele in combination with a normal, decreased, or no function allele may have decreased metabolism/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the ph... | https://www.clinpgx.org/clinicalAnnotation/982047500 |
982047500 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11, CYP2C9*13, CYP2C9*14, CYP2C9*16, CYP2C9*29, CYP2C9*31, CYP2C9*33, CYP2C9*37, CYP2C9*39, CYP2C9*42, CYP2C9*43, CYP2C9*45, CYP2C9*50, CYP2C9*52, CYP2C9*55 | null | CYP2C9 | *16 | 1A | Metabolism/PK | phenytoin | Epilepsy | The CYP2C9*16 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *16 allele in combination with a normal, decreased, or no function allele may have decreased metabolism/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the ph... | https://www.clinpgx.org/clinicalAnnotation/982047500 |
982047500 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11, CYP2C9*13, CYP2C9*14, CYP2C9*16, CYP2C9*29, CYP2C9*31, CYP2C9*33, CYP2C9*37, CYP2C9*39, CYP2C9*42, CYP2C9*43, CYP2C9*45, CYP2C9*50, CYP2C9*52, CYP2C9*55 | null | CYP2C9 | *2 | 1A | Metabolism/PK | phenytoin | Epilepsy | The CYP2C9*2 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *2 allele in combination with a normal, decreased, or no function allele may have decreased metabolism/clearance of phenytoin as compared to patients with two normal function alleles. However, conflicting evidence has be... | https://www.clinpgx.org/clinicalAnnotation/982047500 |
982047500 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11, CYP2C9*13, CYP2C9*14, CYP2C9*16, CYP2C9*29, CYP2C9*31, CYP2C9*33, CYP2C9*37, CYP2C9*39, CYP2C9*42, CYP2C9*43, CYP2C9*45, CYP2C9*50, CYP2C9*52, CYP2C9*55 | null | CYP2C9 | *29 | 1A | Metabolism/PK | phenytoin | Epilepsy | The CYP2C9*29 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *29 allele in combination with a normal, decreased, or no function allele may have decreased metabolism/clearance of phenytoin as compared to patients with two normal function alleles. However, conflicting evidence has ... | https://www.clinpgx.org/clinicalAnnotation/982047500 |
982047500 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11, CYP2C9*13, CYP2C9*14, CYP2C9*16, CYP2C9*29, CYP2C9*31, CYP2C9*33, CYP2C9*37, CYP2C9*39, CYP2C9*42, CYP2C9*43, CYP2C9*45, CYP2C9*50, CYP2C9*52, CYP2C9*55 | null | CYP2C9 | *3 | 1A | Metabolism/PK | phenytoin | Epilepsy | The CYP2C9*3 allele has been assigned as a no function allele by CPIC. Patients carrying the *3 allele in combination with a normal, decreased, or no function allele may have decreased metabolism/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacokin... | https://www.clinpgx.org/clinicalAnnotation/982047500 |
982047500 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11, CYP2C9*13, CYP2C9*14, CYP2C9*16, CYP2C9*29, CYP2C9*31, CYP2C9*33, CYP2C9*37, CYP2C9*39, CYP2C9*42, CYP2C9*43, CYP2C9*45, CYP2C9*50, CYP2C9*52, CYP2C9*55 | null | CYP2C9 | *31 | 1A | Metabolism/PK | phenytoin | Epilepsy | The CYP2C9*31 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *31 allele in combination with a normal, decreased, or no function allele may have decreased metabolism/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the ph... | https://www.clinpgx.org/clinicalAnnotation/982047500 |
982047500 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11, CYP2C9*13, CYP2C9*14, CYP2C9*16, CYP2C9*29, CYP2C9*31, CYP2C9*33, CYP2C9*37, CYP2C9*39, CYP2C9*42, CYP2C9*43, CYP2C9*45, CYP2C9*50, CYP2C9*52, CYP2C9*55 | null | CYP2C9 | *33 | 1A | Metabolism/PK | phenytoin | Epilepsy | The CYP2C9*33 allele has been assigned as a no function allele by CPIC. Patients carrying the *33 allele in combination with a normal, decreased, or no function allele may have decreased metabolism/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacok... | https://www.clinpgx.org/clinicalAnnotation/982047500 |
982047500 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11, CYP2C9*13, CYP2C9*14, CYP2C9*16, CYP2C9*29, CYP2C9*31, CYP2C9*33, CYP2C9*37, CYP2C9*39, CYP2C9*42, CYP2C9*43, CYP2C9*45, CYP2C9*50, CYP2C9*52, CYP2C9*55 | null | CYP2C9 | *37 | 1A | Metabolism/PK | phenytoin | Epilepsy | The CYP2C9*37 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *37 allele in combination with a normal, decreased, or no function allele may have decreased metabolism/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the ph... | https://www.clinpgx.org/clinicalAnnotation/982047500 |
982047500 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11, CYP2C9*13, CYP2C9*14, CYP2C9*16, CYP2C9*29, CYP2C9*31, CYP2C9*33, CYP2C9*37, CYP2C9*39, CYP2C9*42, CYP2C9*43, CYP2C9*45, CYP2C9*50, CYP2C9*52, CYP2C9*55 | null | CYP2C9 | *39 | 1A | Metabolism/PK | phenytoin | Epilepsy | The CYP2C9*39 allele has been assigned as a no function allele by CPIC. Patients carrying the *39 allele in combination with a normal, decreased, or no function allele may have decreased metabolism/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacok... | https://www.clinpgx.org/clinicalAnnotation/982047500 |
982047500 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11, CYP2C9*13, CYP2C9*14, CYP2C9*16, CYP2C9*29, CYP2C9*31, CYP2C9*33, CYP2C9*37, CYP2C9*39, CYP2C9*42, CYP2C9*43, CYP2C9*45, CYP2C9*50, CYP2C9*52, CYP2C9*55 | null | CYP2C9 | *42 | 1A | Metabolism/PK | phenytoin | Epilepsy | The CYP2C9*42 allele has been assigned as a no function allele by CPIC. Patients carrying the *42 allele in combination with a normal, decreased, or no function allele may have decreased metabolism/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacok... | https://www.clinpgx.org/clinicalAnnotation/982047500 |
982047500 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11, CYP2C9*13, CYP2C9*14, CYP2C9*16, CYP2C9*29, CYP2C9*31, CYP2C9*33, CYP2C9*37, CYP2C9*39, CYP2C9*42, CYP2C9*43, CYP2C9*45, CYP2C9*50, CYP2C9*52, CYP2C9*55 | null | CYP2C9 | *43 | 1A | Metabolism/PK | phenytoin | Epilepsy | The CYP2C9*43 allele has been assigned as a no function allele by CPIC. Patients carrying the *43 allele in combination with a normal, decreased, or no function allele may have decreased metabolism/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacok... | https://www.clinpgx.org/clinicalAnnotation/982047500 |
982047500 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11, CYP2C9*13, CYP2C9*14, CYP2C9*16, CYP2C9*29, CYP2C9*31, CYP2C9*33, CYP2C9*37, CYP2C9*39, CYP2C9*42, CYP2C9*43, CYP2C9*45, CYP2C9*50, CYP2C9*52, CYP2C9*55 | null | CYP2C9 | *45 | 1A | Metabolism/PK | phenytoin | Epilepsy | The CYP2C9*45 allele has been assigned as a no function allele by CPIC. Patients carrying the *45 allele in combination with a normal, decreased, or no function allele may have decreased metabolism/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the pharmacok... | https://www.clinpgx.org/clinicalAnnotation/982047500 |
982047500 | CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11, CYP2C9*13, CYP2C9*14, CYP2C9*16, CYP2C9*29, CYP2C9*31, CYP2C9*33, CYP2C9*37, CYP2C9*39, CYP2C9*42, CYP2C9*43, CYP2C9*45, CYP2C9*50, CYP2C9*52, CYP2C9*55 | null | CYP2C9 | *5 | 1A | Metabolism/PK | phenytoin | Epilepsy | The CYP2C9*5 allele has been assigned as a decreased function allele by CPIC. Patients carrying the *5 allele in combination with a normal, decreased, or no function allele may have decreased metabolism/clearance of phenytoin as compared to patients with two normal function alleles. This annotation only covers the phar... | https://www.clinpgx.org/clinicalAnnotation/982047500 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.